Research Analysts Set Expectations for PDSB Q3 Earnings

PDS Biotechnology Corporation (NASDAQ:PDSB) – Research analysts at HC Wainwright boosted their Q3 2026 earnings estimates for PDS Biotechnology in a research report issued on Thursday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.12) for the quarter, up from their previous estimate of ($0.15). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at ($0.33) EPS.

Several other research analysts also recently issued reports on PDSB. Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Price Performance

Shares of PDS Biotechnology stock opened at $0.21 on Monday. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. The company has a market cap of $11.63 million, a PE ratio of -0.32 and a beta of 1.62. The firm has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $0.84. PDS Biotechnology has a fifty-two week low of $0.21 and a fifty-two week high of $1.55.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05).

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in PDS Biotechnology in the fourth quarter worth $25,000. Bank of New York Mellon Corp bought a new stake in PDS Biotechnology in the 2nd quarter valued at $60,000. Marshall Wace LLP bought a new stake in PDS Biotechnology in the 2nd quarter valued at $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter valued at about $92,000. Finally, Susquehanna International Group LLP boosted its position in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after acquiring an additional 80,937 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.